000127011 001__ 127011
000127011 005__ 20241125101155.0
000127011 0247_ $$2doi$$a10.1007/s10549-023-07002-1
000127011 0248_ $$2sideral$$a134311
000127011 037__ $$aART-2023-134311
000127011 041__ $$aeng
000127011 100__ $$aMartín, Miguel
000127011 245__ $$aLong-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
000127011 260__ $$c2023
000127011 5060_ $$aAccess copy available to the general public$$fUnrestricted
000127011 5203_ $$aPurpose
The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to the monarchE trial to put into context the potential benefit of abemaciclib.
Methods
HR-positive/HER2-negative EBC patients eligible for the monarchE study were selected from 3 adjuvant clinical trials and a breast cancer registry. Patients with ≥ 4 positive axillary lymph nodes (N +) or 1–3 N + with tumor size ≥ 5 cm and/or histologic grade 3 and/or Ki67 ≥ 20%, who had undergone surgery with curative intent and had received anthracyclines ± taxanes and endocrine therapy in the neoadjuvant and /or adjuvant setting were included. We performed analysis of Invasive Disease-Free Survival (iDFS), Distant Disease-Free Survival (dDFS) and Overall Survival (OS) at 5 and 10 years, as well as yearly (up to 10) of Invasive Relapse Rate (IRR), Distant Relapse Rate (DRR) and Death Rate (DR).
Results
A total of 1,617 patients were analyzed from the GEICAM-9906 (312), GEICAM-2003–10 (210), and GEICAM-2006–10 (160) trials plus 935 from El Álamo IV. With a median follow-up of 10.1 years, the 5 and 10 years iDFS rates were 75.2% and 57.0%, respectively. The dDFS and OS rates at 5 years were 77.4% and 88.8% and the respective figures at 10 years were 59.7% and 70.9%.
Conclusions
This data points out the need for new therapies for those patients. A longer follow-up of the monarchE study to see the real final benefit with abemaciclib is warranted.
000127011 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000127011 590__ $$a3.0$$b2023
000127011 592__ $$a1.267$$b2023
000127011 591__ $$aONCOLOGY$$b142 / 322 = 0.441$$c2023$$dQ2$$eT2
000127011 593__ $$aOncology$$c2023$$dQ1
000127011 593__ $$aCancer Research$$c2023$$dQ2
000127011 594__ $$a6.8$$b2023
000127011 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000127011 700__ $$aCarrasco, Eva
000127011 700__ $$aRodríguez-Lescure, Álvaro
000127011 700__ $$0(orcid)0000-0003-0123-4274$$aAndrés, Raquel$$uUniversidad de Zaragoza
000127011 700__ $$aServitja, Sonia
000127011 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, Antonio$$uUniversidad de Zaragoza
000127011 700__ $$aRuiz-Borrego, Manuel
000127011 700__ $$aBermejo, Begoña
000127011 700__ $$aGuerrero, Ángel
000127011 700__ $$aRamos, Manuel
000127011 700__ $$aSantaballa, Ana
000127011 700__ $$aMuñoz, Montserrat
000127011 700__ $$aCruz, Josefina
000127011 700__ $$aLopez-Tarruella, Sara
000127011 700__ $$aChacón, Jose I.
000127011 700__ $$aÁlvarez, Isabel
000127011 700__ $$aMartínez, Purificación
000127011 700__ $$aMiralles, Juan J.
000127011 700__ $$aPolonio, Óscar
000127011 700__ $$aJara, Carlos
000127011 700__ $$aAguiar-Bujanda, David
000127011 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000127011 773__ $$g201, 2 (2023), 151-159$$pBreast cancer res. treat.$$tBREAST CANCER RESEARCH AND TREATMENT$$x0167-6806
000127011 8564_ $$s966489$$uhttps://zaguan.unizar.es/record/127011/files/texto_completo.pdf$$yVersión publicada
000127011 8564_ $$s2280864$$uhttps://zaguan.unizar.es/record/127011/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000127011 909CO $$ooai:zaguan.unizar.es:127011$$particulos$$pdriver
000127011 951__ $$a2024-11-22-12:08:38
000127011 980__ $$aARTICLE